{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'review the interim efficacy analyses for OS. If requested, the IDMC may have access to the', 'treatment allocation code or any other requested data for the purposes of a risk-benefit assessment.', 'The IDMC will provide the sponsor with appropriate recommendations on the conduct of the', 'clinical study to ensure the protection and safety of the patients enrolled in the study. The IDMC', 'will also institute any measures that may be required for ensuring the integrity of the study results', 'during the study execution. The IDMC will act in an advisory capacity to Regeneron. Regeneron', 'will have responsibility for the overall design and conduct of the study including communication', 'of the data.', 'All activities and responsibilities of the IDMC are described in the IDMC charter.', '5.3.2.', 'Trial Steering Committee', 'All activities of the Trial Steering Committee (TSC) are described in the TSC charter.', '5.4.', 'Study Conduct in Response to COVID-19', 'Included in amendment 6 of the protocol are measures to account for the \"Coronavirus Disease', '2019\" (COVID-19) pandemic and to minimize the risks to the patients in the study as well as', 'healthcare providers.', '6.', 'SELECTION, WITHDRAWAL, AND REPLACEMENT OF', 'PATIENTS', '6.1.', 'Number of Patients Planned', 'Approximately 460 SCC patients will be randomized 1:1 (230 per treatment arm) at approximately', '100 sites globally. Approximately 590 patients in the overall population are projected to have', 'accrued when the enrollment for SCC patients is completed. However, the actual number of', 'patients in the overall population depends on the proportion of adenocarcinoma patients in the', 'patient population and the time when Amendment 5 is implemented at each of the study sites.', '6.2.', 'Study Population', 'The study will enroll women >18 years old with recurrent, persistent, and/or metastatic cervical', 'cancer that has progressed after platinum-containing chemotherapy given to treat recurrent or', 'metastatic cervical cancer. Patients who have only received prior platinum-based therapy', 'concurrently with radiation therapy for localized disease are not eligible. Starting with', 'Amendment 5, only patients with squamous histology will be enrolled.', '6.2.1.', 'Inclusion Criteria', 'A patient must meet the following criteria to be eligible for inclusion in the study:', '1. Recurrent, persistent, and/or metastatic cervical cancer with squamous cell histology, for', 'which there is not a curative-intent option (surgery or radiation therapy with or without', 'chemotherapy).', 'Regeneron Pharmaceuticals, Inc.', 'Page 47 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'a. Patients with acceptable histologies (squamous carcinoma, adenocarcinoma, and AC)', 'will be enrolled from the original protocol through protocol Amendment 4. For the', 'purpose of this study, AC will be stratified as adenocarcinoma.', 'b. Starting with protocol Amendment 5, only patients with squamous cell histology are', 'eligible to enroll.', '2. Tumor progression or recurrence after treatment with platinum therapy (must have been used', 'to treat metastatic, persistent, or recurrent cervical cancer).', 'NOTE: Platinum-therapy given in other settings (eg, concurrent with radiation therapy as', 'part of curative-intent therapy, after radiation [or chemoradiation] as adjuvant treatment in', 'a', 'patient with no evidence of disease) does not satisfy the eligibility requirement regarding', 'prior platinum therapy.', '3. Patient must have measurable disease as defined by RECIST 1.1. Measurable disease is', 'defined as at least one lesion that can be accurately measured in at least 1 dimension (longest', 'dimension to be recorded). Each lesion must be >10 mm when measured by computed', 'tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical', 'exam or must be >20 mm when measured by chest x-ray. Lymph nodes must be >15 mm in', 'short axis when measured by CT or MRI.', 'Tumors within a previously irradiated field will be designated as non-measurable lesions', 'unless progression is documented or a biopsy is obtained to confirm persistence at least', '90 days following completion of radiation therapy.', '4. Eastern Cooperative Oncology Group (ECOG) performance status 1', '5. >18 years old', 'NOTE: For patients enrolling in Japan who are >18 and <20 years old, both the patients', 'and parent/legal representative must provide signed informed consent.', '6. Hepatic function:', 'a.', 'Total bilirubin <1.5x upper limit of normal (ULN; if liver metastases <3x ULN).', \"Patients with Gilbert's Disease and total bilirubin up to 3x ULN may be eligible after\", 'communication with and approval from the medical monitor.', 'b. Transaminases <3x ULN (or <5.0x ULN, if liver metastases)', 'c. Alkaline phosphatase 2. 5x ULN (or <5.0x ULN, if liver or bone metastases)', 'NOTE: For patients with hepatic metastases, if transaminase levels (aspartate', 'aminotransferase [AST] and/or alanine aminotransferase [ALT]) >3x but <5x ULN, total', 'bilirubin must be <1.5x ULN. If total bilirubin >1.5x but <3x ULN, both transaminases', '(AST and ALT) must be <3x ULN.', '7. Renal function: Serum creatinine <1.5x ULN or estimated creatinine clearance >45 mL/min', '8. Bone marrow function:', 'a.', 'Hemoglobin >9.0 g/dL', 'b. Absolute neutrophil count (ANC) >1.5x 109/L', 'c. Platelet count >75 x 109/L', 'Regeneron Pharmaceuticals, Inc.', 'Page 48 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}